Skip to main content

Table 1 Baseline characteristics, cART regimens and responses of the women who commenced cART during pregnancy

From: An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy

Values are median (IQR) or total (%) Women initiating cART during index pregnancy and with a quantifiable HIV RNA at day 14
(n = 192)
Women initiating cART during index pregnancy and with HIV RNA below the limits of quantification at day 14
(n = 29)
Age (years) 31.0 (26.5, 34.0) 31.0 (25.5, 36.0)
Black African and/or Caribbean ethnicity 160 (83.3) 26 (89.7)
HIV acquired via heterosexual intercourse 189 (98.5) 28 (96.6)
Hepatitis B and/or C co-infection 2 (1.0) 4 (13.7)
Received cART previously 70 (36.5) 9 (31.0)
Gestational age when cART initiated, weeks 20.8 (16.9, 24.4) 21.9 (19.0, 24.3)
Baseline CD4+ T-cell count, cells/µL 339 (212, 481) 520 (334–637)
Baseline plasma HIV RNA, log10 copies/mL 4.2 (3.8, 4.7) 3.1 (2.9–3.6)
Plasma HIV RNA 14 days after initiating cART, log10 copies/mL 2.4 (2.1, 2.9) All < 1.7
First-phase HIV RNA half-life decay, days 2.5 (2.1, 3.0) 2.9 (2.2, 3.6)
Women with pVL < 50 copies/mL at 36 weeks’ gestation 139 (72.4) 29 (100)
Women with pVL < 50 copies/mL at delivery 163 (84.9) 29 (100)
Gestational age at delivery, weeks 39.1 (38.0, 40.4) 39.0 (38.0, 40.0)
cART regimen used   
 ABC/3TC/AZT 11 (5.7) 3 (10.3)
 Dual NRTI backbone 181 (94.3) 26 (89.7)
  AZT + 3TC 75 (39.1) 11 (37.9)
  ABC + 3TC 41 (21.4) 6 (20.7)
  TDF + FTC 65 (33.9) 9 (31.0)
 Dual NRTI backbone + PI 132 (68.8) 20 (69.0)
  Atazanavir/ritonavir 60 (31.1) 9 (31.0)
  Darunavir/ritonavir 11 (5.7) 1 (3.4)
  Lopinavir/ritonavir 50 (26.0) 3 (10.3)
  Saquinavir/ritonavir 11 (5.7) 7 (24.1)
 Dual NRTI backbone + NNRTI 32 (16.7) 2 (6.9)
  Nevirapine 26 (13.5) 2 (6.9)
  Efavirenz 5 (2.6) 0
  Rilpivirine 1 (0.5) 0
 Dual NRTI backbone + INSTI 17 (8.9) 4 (13.8)
  Raltegravir 11 (5.7) 1 (3.4)
  Dolutegravir 6 (3.1) 3 (10.3)
Infant HIV status at birth   
 HIV negative 150 (78.1) 21 (72.4)
 Data not available 42 (21.9) 8 (27.6)
  1. Baseline characteristics, antiretroviral treatment regimens and responses of the 221 women living with HIV, who commenced combination antiretroviral therapy during index pregnancy
  2. IQR interquartile range, cART combination antiretroviral treatment, ABC abacavir, 3TC lamivudine, AZT zidovudine, TDF tenofovir disoproxil fumarate, FTC emtricitabine, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, INSTI integrase strand transferase inhibitor
\